EN PL
ORIGINAL PAPER
Figure from article: Methotrexate-related...
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The study aimed to assess the beliefs and fears of Moroccan patients with rheumatoid arthritis (RA) regarding methotrexate (MTX) and to identify factors associated with the total score on the Beliefs about Medicines Questionnaire-Specific (BMQ).

Material and methods:
A single-center cross-sectional study was conducted in patients being treated for RA with MTX. Beliefs about treatment were assessed using the BMQ. Specific fears related to MTX were collected using a structured questionnaire developed for the study. Factors associated with the total BMQ score were explored using univariate and then multivariate linear regression.

Results:
One hundred and two patients were included (age: 53.1 ±12.5 years; 90.2% women). The mean BMQ-Concerns score was 15.9 ±6.37. The main concerns were related to potential long-term adverse effects (58.8%), particularly gastrointestinal (65.7%) and hepatic (62.7%) toxicity. A moderate or high level of fear was reported by 53.9% of patients. The mean BMQ-Necessity score was 15.0 ±5.04; 55% felt that their current health depended on MTX, and 51% perceived an overall benefit from the treatment. The median BMQ total score was 1 (from –3 to 4). In multivariate analysis, longer disease duration (β = –0.12; 95% CI: –0.23 to –0.02) and use of the internet as a source of information (β = –2.66; 95% CI: –5.06 to –0.27) were independently associated with the total score.

Conclusions:
Moroccan patients with RA generally consider MTX to be necessary but express significant concerns about its toxicity. Disease duration and use of the internet significantly influence these perceptions, highlighting the need for therapeutic education interventions and reliable digital information sources.
REFERENCES (28)
1.
Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 2023; 82: 3–18, DOI: 10.1136/ard-2022-223356.
 
2.
Fautrel B, Kedra J, Rempenault C, et al. 2024 update of the recommendations of the French Society of Rheumatology for the diagnosis and management of patients with rheumatoid arthritis. Joint Bone Spine 2024; 91: 105790, DOI: 10.1016/ j.jbspin.2024.105790.
 
3.
Fellous S, Rkain H, Ahid S, et al. One-year direct costs of biological therapy in rheumatoid arthritis and its predictive factors: data from the Moroccan RBSMR registry. Rheumatol Int 2021; 41: 787–793, DOI: 10.1007/s00296-020-04762-7.
 
4.
Buch MH, Eyre S, McGonagle D. Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat Rev Rheumatol 2021; 17: 17–33, DOI: 10.1038/s41584-020-00541-7.
 
5.
Chowdhury T, Dutta J, Noel P, et al. An Overview on Causes of Nonadherence in the Treatment of Rheumatoid Arthritis: Its Effect on Mortality and Ways to Improve Adherence. Cureus 2022; 14: e24520, DOI: 10.7759/cureus.24520.
 
6.
van den Bemt BJ, Zwikker HE, van den Ende CH. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol 2012; 8: 337–351, DOI: 10.1586/eci.12.23.
 
7.
Nalwa HS, Prasad P, Ganguly NK, et al. Methotrexate intolerance in rheumatoid arthritis. Transl Med Commun 2023; 8: 10, DOI: 10.1186/s41231-023-00142-y.
 
8.
Curtis JR, Xie F, Mackey D, et al. Patient’s experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis. BMC Musculoskelet Disord 2016; 17: 405, DOI: 10.1186/s12891-016-1254-x.
 
9.
Hua C, Combe B. The new ACR/EULAR 2010 classification criteria for an earlier rheumatoid arthritis diagnosis. Revue du Rhumatisme Monographies 2017; 84: 337–342, DOI: 10.1016/ j.monrhu.2017.07.001.
 
10.
Hayden C, Neame R, Tarrant C. Patients’ adherence-related beliefs about methotrexate: a qualitative study of the role of written patient information. BMJ Open 2015; 5: e006918, DOI: 10.1136/bmjopen-2014-006918.
 
11.
Tornero Molina J, López Robledillo JC, Casamira Ruiz N. Potential Benefits of the Self-Administration of Subcutaneous Methotrexate with Autoinjector Devices for Patients: a Review. Drug Healthc Patient Saf 2021; 13: 81–94, DOI: 10.2147/DHPS.S290771.
 
12.
Zimba O, Gasparyan AY. Designing, Conducting, and Reporting Survey Studies: A Primer for Researchers. J Korean Med Sci 2023; 38: e403, DOI: 10.3346/jkms.2023.38.e403.
 
13.
Alhalaiqa F, Masa’Deh R, Batiha AM, et al. Validity of Arabic Version of beliefs about Medication Questionnaire. Clin Nurs Res 2015; 24: 539–555, DOI: 10.1177/1054773814545383.
 
14.
Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999; 14: 1–24, DOI: 10.1080/ 08870449908407311.
 
15.
Sherbini AA, Gwinnutt JM, Hyrich KL; RAMS Co-Investigators, Verstappen SMM. Rates and predictors of methotrexate- related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study. Rheumatology (Oxford) 2022; 61: 3930–3938, DOI: 10.1093/rheumatology/keab917.
 
16.
Zekić T, Blažić F, Katalinić N, et al. Methotrexate and biological therapy are not associated with fatty liver in rheumatoid arthritis-a cross-sectional study. Rheumatol Int 2025; 45: 236, DOI: 10.1007/s00296-025-05987-0.
 
17.
AkbariRad M, Rezaieyazdi Z, Tajik A, et al. The relationship between dose of methotrexate and incidence of liver fibrosis in patients with rheumatoid arthritis. Reumatologia 2025; 63: 3–11, DOI: 10.5114/reum/199740.
 
18.
Palominos PE, Gasparin AA, de Andrade NPB, et al. Fears and beliefs of people living with rheumatoid arthritis: a systematic literature review. Adv Rheumatol 2018; 58: 1, DOI: 10.1186/s42358-018-0001-4.
 
19.
Abdulridha SH, Kadhim DJ, Razzak SAA. Beliefs about Medicines among a Sample of Iraqi patients with Psoriasis. Innov Pharm 2021; 12: 10.24926/iip.v12i1.3584, DOI: 10.24926/iip.v12i1.3584.
 
20.
Tosato S, Bonetto C, Zanini A, et al. Clinical and psychological characteristics associated with negative beliefs and concerns about treatment necessity in rheumatic diseases. Sci Rep 2022; 12: 22603, DOI: 10.1038/s41598-022-27046-5.
 
21.
Otón T, Carmona L, Andreu JL. What do patients on methotre­xate need and expect at the clinic? An online patient survey. Rheumatol Int 2023; 43: 735–741, DOI: 10.1007/s00296-022-05249-3.
 
22.
Lim HM, Dunn AG, Lim JR, et al. Association between online health information-seeking and medication adherence: A systematic review and meta-analysis. Digit Health 2022; 8: 20552076221097784, DOI: 10.1177/20552076221097784.
 
23.
Sharma C, Whittle S, Haghighi PD, et al. Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis. Ann Rheum Dis 2020; 79: 1432–1437, DOI: 10.1136/annrheumdis-2020-217333.
 
24.
Thapa DK, Visentin DC, Kornhaber R, et al. The influence of online health information on health decisions: A systematic review. Patient Educ Couns 2021; 104: 770–784, DOI: 10.1016/ j.pec.2020.11.016.
 
25.
Kumar K, Gordon C, Toescu V, et al. Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: a comparison between patients of South Asian and White British origin. Rheumatology (Oxford) 2008; 47: 690–697, DOI: 10.1093/rheumatology/ken050.
 
26.
Barton JL, Trupin L, Tonner C, et al. English language proficiency, health literacy, and trust in physician are associated with shared decision making in rheumatoid arthritis. J Rheumatol 2014; 41: 1290–1297, DOI: 10.3899/jrheum.131350.
 
27.
Martin RW, Head AJ, René J, et al. Patient decision-making related to antirheumatic drugs in rheumatoid arthritis: the importance of patient trust of physician. J Rheumatol 2008; 35: 618–624.
 
28.
McCulley C, Katz P, Trupin L, et al. Association of Medication Beliefs, Self-efficacy, and Adherence in a Diverse Cohort of Adults with Rheumatoid Arthritis. J Rheumatol 2018; 45: 1636–1642, DOI: 10.3899/jrheum.171339.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top